PAVmed Management
Management criteria checks 3/4
PAVmed's CEO is Lishan Aklog, appointed in Jun 2014, has a tenure of 10.67 years. total yearly compensation is $953.20K, comprised of 95.8% salary and 4.2% bonuses, including company stock and options. directly owns 3.4% of the company’s shares, worth $249.55K. The average tenure of the management team and the board of directors is 2.4 years and 10.1 years respectively.
Key information
Lishan Aklog
Chief executive officer
US$953.2k
Total compensation
CEO salary percentage | 95.8% |
CEO tenure | 10.7yrs |
CEO ownership | 3.4% |
Management average tenure | 2.4yrs |
Board average tenure | 10.1yrs |
Recent management updates
Recent updates
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?
Jan 29Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?
Aug 17PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
Aug 16PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress
Jul 05Start Accumulating PAVmed
Dec 24We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth
Sep 02PAVmed: Long Term Investment Case Remains Despite Weak Q2
Aug 23PAVmed: A True Game-Changer For Medical Device Innovation
Jun 14PAVmed forms digital health company, Veris Health
Jun 02PAVmed's subsidiary receives CE mark for EsoCheck esophageal cell collection device
May 26PAVmed (NASDAQ:PAVM) Is In A Good Position To Deliver On Growth Plans
May 19PAVmed drops 14% on launch of $13.4M direct offering
Jan 06PAVmed closes additional direct offering of common stock
Dec 22Do Institutions Own PAVmed Inc. (NASDAQ:PAVM) Shares?
Dec 16PAVmed offers stock for $8.9M
Dec 11PAVmed EPS beats by $0.02
Nov 17There Is Progress At PAVmed, But More Patience Is Required
Oct 30CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | US$15m |
Jun 30 2024 | n/a | n/a | -US$67m |
Mar 31 2024 | n/a | n/a | -US$71m |
Dec 31 2023 | US$953k | US$913k | -US$66m |
Sep 30 2023 | n/a | n/a | -US$71m |
Jun 30 2023 | n/a | n/a | -US$79m |
Mar 31 2023 | n/a | n/a | -US$90m |
Dec 31 2022 | US$1m | US$901k | -US$89m |
Sep 30 2022 | n/a | n/a | -US$86m |
Jun 30 2022 | n/a | n/a | -US$72m |
Mar 31 2022 | n/a | n/a | -US$58m |
Dec 31 2021 | US$9m | US$583k | -US$51m |
Sep 30 2021 | n/a | n/a | -US$42m |
Jun 30 2021 | n/a | n/a | -US$35m |
Mar 31 2021 | n/a | n/a | -US$30m |
Dec 31 2020 | US$1m | US$431k | -US$35m |
Sep 30 2020 | n/a | n/a | -US$32m |
Jun 30 2020 | n/a | n/a | -US$30m |
Mar 31 2020 | n/a | n/a | -US$28m |
Dec 31 2019 | US$890k | US$431k | -US$17m |
Sep 30 2019 | n/a | n/a | -US$17m |
Jun 30 2019 | n/a | n/a | -US$17m |
Mar 31 2019 | n/a | n/a | -US$19m |
Dec 31 2018 | US$772k | US$346k | -US$19m |
Compensation vs Market: Lishan's total compensation ($USD953.20K) is above average for companies of similar size in the US market ($USD640.92K).
Compensation vs Earnings: Lishan's compensation has been consistent with company performance over the past year.
CEO
Lishan Aklog (58 yo)
10.7yrs
Tenure
US$953,200
Compensation
Dr. Lishan Aklog, M.D., serves as Executive Chairman at Veris Health Inc. since April 2023. He served as Independent Director at ContraFect Corporation since June 14, 2020 until December 04, 2023. Dr. Aklo...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 10.7yrs | US$953.20k | 3.4% $ 249.6k | |
President & CFO | 7.9yrs | US$673.50k | 0.46% $ 33.8k | |
Executive VP & COO | 3yrs | US$498.00k | 0.16% $ 11.9k | |
Executive VP | 2.8yrs | US$710.50k | 0% $ 0 | |
Executive VP | 1.8yrs | US$593.10k | no data | |
Senior VP of Molecular Genetics & Chief Scientific Officer | 2.1yrs | no data | no data | |
Vice President of Investor Relations | no data | no data | no data | |
Senior VP | 2.1yrs | no data | no data | |
Senior VP & Chief Medical Officer | 2.1yrs | no data | no data |
2.4yrs
Average Tenure
58yo
Average Age
Experienced Management: PAVM's management team is considered experienced (2.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman & CEO | 10.7yrs | US$953.20k | 3.4% $ 249.6k | |
Independent Director | 10.1yrs | US$251.90k | 0.59% $ 43.2k | |
Member of Medical Advisory Board | 10.3yrs | no data | no data | |
Independent Director | 3.7yrs | US$238.90k | 0.59% $ 43.2k | |
Member of Medical Advisory Board | 10.3yrs | no data | no data | |
Member of Medical Advisory Board | 10.1yrs | no data | no data | |
Member of Medical Advisory Board | 10.1yrs | no data | no data | |
Independent Vice Chairman | 10.3yrs | US$228.90k | 0.74% $ 54.2k | |
Member of Medical Advisory Board | 10.3yrs | no data | no data | |
Independent Director | 3.8yrs | US$248.90k | 0.59% $ 43.2k | |
Member of Medical Advisory Board | 8.3yrs | no data | no data | |
Member of Medical Advisory Board | 7.3yrs | no data | no data |
10.1yrs
Average Tenure
62yo
Average Age
Experienced Board: PAVM's board of directors are seasoned and experienced ( 10.1 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/02/02 01:38 |
End of Day Share Price | 2025/01/31 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PAVmed Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Edward Woo | Ascendiant Capital Markets LLC |
Raymond Myers | Benchmark Company |
Charles Duncan | Cantor Fitzgerald & Co. |